Search results for "Adenovirus Vaccines"

showing 2 items of 2 documents

Additives for vaccine storage to improve thermal stability of adenoviruses from hours to months

2016

Up to 80% of the cost of vaccination programmes is due to the cold chain problem (that is, keeping vaccines cold). Inexpensive, biocompatible additives to slow down the degradation of virus particles would address the problem. Here we propose and characterize additives that, already at very low concentrations, improve the storage time of adenovirus type 5. Anionic gold nanoparticles (10−8–10−6 M) or polyethylene glycol (PEG, molecular weight ∼8,000 Da, 10−7–10−4 M) increase the half-life of a green fluorescent protein expressing adenovirus from ∼48 h to 21 days at 37 °C (from 7 to >30 days at room temperature). They replicate the known stabilizing effect of sucrose, but at several orders of…

0301 basic medicineSucroseSucroseTime FactorsvirusesGeneral Physics and AstronomyMetal Nanoparticles02 engineering and technologyvaccinationsvaccine storagePolyethylene Glycolschemistry.chemical_compoundMiceImmunogenicity VaccineDrug StabilityModelsAdenovirus Vaccinesvaccineta318ta317MultidisciplinaryChemistryImmunogenicityadenoviruksetQadenovirus021001 nanoscience & nanotechnologyImmunogenicityOrders of magnitude (mass)Cold Temperaturevaccine; adenovirus; additives; nanoparticlesInfectious DiseasesColloidal goldModels Animaladditives0210 nano-technologyInfectionBiotechnologyHalf-LifeScienceDrug StorageBioengineeringPolyethylene glycolModels BiologicalGeneral Biochemistry Genetics and Molecular BiologyArticleVaccine RelatedExcipients03 medical and health sciencesPEG ratioAnimalsThermal stabilityChromatographyAnimalPreventionRational designta1182General ChemistryBiologicalVirology030104 developmental biologyadenovirusesFeasibility StudiesImmunizationnanoparticlesGoldVaccine
researchProduct

GRAd-COV2, a gorilla adenovirus-based candidate vaccine against COVID-19, is safe and immunogenic in younger and older adults

2022

International audience; Safe and effective vaccines against coronavirus disease 2019 (COVID-19) are essential for ending the ongoing pandemic. Although impressive progress has been made with several COVID-19 vaccines already approved, it is clear that those developed so far cannot meet the global vaccine demand alone. We describe a COVID-19 vaccine based on a replication-defective gorilla adenovirus expressing the stabilized prefusion severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein named GRAd-COV2. We assessed the safety and immunogenicity of a single-dose regimen of this vaccine in healthy younger and older adults to select the appropriate dose for each age group…

2019-20 coronavirus outbreakCOVID-19 VaccinesSettore BIO/06Coronavirus disease 2019 (COVID-19)COVID-19 VaccineSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)GorillaAdenoviridaeAdenovirus Vaccinesbiology.animalPandemicAnimalsHumansMedicineMESH: COVID-19MESH: AnimalsMESH: SARS-CoV-2AgedMESH: Adenovirus VaccinesMESH: AgedGorilla gorilla[SDV.MHEP] Life Sciences [q-bio]/Human health and pathologyMESH: HumansbiologyAnimalSARS-CoV-2business.industryMESH: Gorilla gorillaCOVID-19MESH: AdenoviridaeGeneral MedicineVirologyAdenovirus VaccineMESH: COVID-19 Vaccinesbusiness[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologyHuman
researchProduct